Overview

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Status:
Completed
Trial end date:
2011-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in subjects recently diagnosed with type 1 diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Mesoblast International Sàrl
Mesoblast, Inc.
Collaborator:
Juvenile Diabetes Research Foundation
Treatments:
Remestemcel-l